The UK government has confirmed eligible CE-marked medical devices and IVDs will continue to be recognized indefinitely in Great Britain. This removes previous uncertainty around future market access. The decision reduces regulatory duplication for manufacturers, supports continued device availability, and provides greater long-term planning certainty. Hence, the previous 2030 deadline has been removed. Notably, manufacturers must still comply with MHRA registration, post-market surveillance, vigilance, labeling, importer, and UK Responsible Person requirements. UKCA marking remains available as the national conformity assessment route. Furthermore, the announcement does not affect Northern Ireland, which continues to operate under a separate regulatory framework.
Eligible CE-marked medical devices and IVDs will continue to be recognized indefinitely in Great Britain: Why is this decision important?
The UK’s decision to indefinitely recognize eligible CE-marked medical devices and IVDs is significant because it provides long-term regulatory stability and ensures continued access to medical technologies in Great Britain. As majority of devices currently available in the UK market rely on CE certification, ending recognition could have created market disruptions, increased costs, and delayed patient access to essential products. The MHRA’s decision helps avoid these risks while supporting innovation and maintaining supply continuity.
Key reasons
- Ensures uninterrupted market access: Manufacturers can continue supplying CE-marked devices to Great Britain without facing immediate regulatory changes or additional transition requirements. This helps maintain a stable supply of medical technologies.
- Reduces regulatory burden: Companies can leverage existing CE certifications rather than pursuing separate conformity assessments solely to remain on the GB market. This reduces compliance complexity and administrative workload.
- Saves time and costs: Avoiding duplicate regulatory processes lowers certification, testing, documentation, and regulatory maintenance costs.
- Improves business planning certainty: Manufacturers can develop long-term regulatory, investment, and commercialization strategies without worrying about future CE recognition deadline.
- Protects patient access to innovation: By continuing to accept CE-marked products, the UK minimizes barriers for innovative medical devices and diagnostics already approved under EU requirements, thereby helping patients access new technologies faster.
- Supports supply chain stability: The decision reduces the risk of manufacturers withdrawing products from the UK market due to additional compliance costs or regulatory uncertainty, thereby helping maintain consistent product availability.
- Maintains UK competitiveness: A more flexible regulatory approach makes the UK market attractive to global manufacturers. Additionally, it encourages continued investment in the healthcare sector.
Thus, this decision means lower compliance costs, reduced regulatory uncertainty, and continued market access to introducing products into UK. Hence, allowing CE-marked medical devices and IVDs to be recognized indefinitely in Great Britain will translate to continued device availability.
Key implications for CE-marked medical device and IVD manufacturers
1. Indefinite access to the Great Britain market
Manufacturers of eligible CE-marked medical devices and IVDs can continue placing their products on the Great Britain market without concerns about a future recognition deadline. This provides long-term certainty for market access and commercial planning.
2. Reduced regulatory complexity
The continued acceptance of CE marking minimizes the need for separate conformity assessment activities solely for Great Britain market entry. Manufacturers can leverage existing EU regulatory approvals while maintaining compliance with applicable UK requirements.
3. Lower compliance costs
Avoiding duplicate regulatory processes can significantly reduce expenses associated with certification, testing, technical documentation updates, and ongoing regulatory maintenance. This is particularly beneficial for small and medium-sized manufacturers.
4. Greater business and investment certainty
The removal of regulatory uncertainty allows manufacturers to make long-term decisions regarding product launches, supply chain investments, market expansion, and resource allocation with greater confidence.
5. Continued availability of innovative devices
Manufacturers can introduce CE-marked innovative medical devices and IVDs into Great Britain more efficiently. This will help reduce market-entry barriers and support faster patient access to advanced healthcare technologies.
6. Improved supply chain stability
The decision lowers the risk of product withdrawals caused by additional regulatory burdens. Manufacturers can maintain a more stable product portfolio in Great Britain and ensure consistent supply to healthcare providers and patients.
7. UKCA marking remains an alternative route
Although CE marking will continue to be recognized indefinitely, UKCA marking remains available as the national conformity assessment route. Manufacturers now have greater flexibility when determining their regulatory strategy for the UK market.
8. Ongoing MHRA compliance obligations
Manufacturers must continue meeting all applicable UK regulatory requirements, including:
- MHRA device registration
- Post-market surveillance
- Vigilance and incident reporting
- Correct labeling requirements
- Importer responsibilities
- UK Responsible Person obligations (where applicable)
The continued recognition of CE marking does not remove these regulatory responsibilities.
9. Simplified global regulatory strategies
Organizations marketing devices in both the EU and Great Britain can align regulatory activities more efficiently. Maintaining CE certification may support access to both markets while reducing duplication of compliance efforts.
10. Strategic advantage for international manufacturers
The UK’s flexible approach makes Great Britain a more attractive market for global manufacturers by reducing regulatory barriers and facilitating continued market participation.
Thus, for CE-marked medical device and IVD manufacturers, the UK’s decision delivers three major benefits: regulatory certainty, reduced compliance burden, and sustained market access. However, companies must continue to fulfill MHRA registration, post-market surveillance, vigilance, labeling, and UK Responsible Person requirements to remain compliant in Great Britain.
Regulatory takeaways for manufacturers
- CE-marked medical devices and IVDs retain indefinite access to Great Britain.
- The previously anticipated 2030 transition deadline has been removed.
- UKCA remains optional as the domestic conformity route.
- MHRA regulatory obligations continue unchanged.
- Northern Ireland remains subject to separate regulatory requirements.
- Manufacturers gain greater predictability for UK market-entry and compliance planning.
Recommended actions for CE-marked medical devices and IVDs manufacturers
- Verify CE marking eligibility: Manufacturers should confirm that their medical devices or IVDs meet the eligibility criteria for continued CE-mark recognition in Great Britain.
- Maintain MHRA registration compliance: All devices placed on the Great Britain market must remain properly registered with the MHRA. Manufacturers should ensure registrations are current and promptly update any changes to device information, certifications, or company details.
- Review UK responsible person requirements: Manufacturers located outside the UK should confirm whether a UK Responsible Person (UKRP) is required. Additionally, they need to verify that appropriate agreements and responsibilities are documented and maintained.
- Strengthen post-market surveillance systems: Organizations should maintain robust post-market surveillance activities. This is necessary to continuously monitor device safety, performance, complaints, adverse events, and emerging risks throughout the product lifecycle.
- Review product labeling and packaging: Companies should assess product labels, Instructions for Use (IFUs), importer details, and UK Responsible Person information to ensure continued compliance with applicable UK requirements.
- Align EU and UK regulatory activities: Manufacturers serving both EU and Great Britain markets should optimize regulatory processes by leveraging CE certification while ensuring compliance with any UK-specific obligations. This can reduce duplication and improve regulatory efficiency.
- Monitor MHRA regulatory updates: The UK regulatory framework continues to evolve. Manufacturers should regularly monitor MHRA guidance, consultations, and legislative developments to identify new compliance obligations and market opportunities.
- Conduct a regulatory gap assessment: Organizations should perform periodic reviews of their quality management system, technical documentation, and registration. Additionally, labeling, vigilance procedures, and supply chain controls have to be monitored to identify and address potential compliance gaps.
Conclusions
The MHRA’s decision removes uncertainty around CE-marked medical devices and IVDs. However, manufacturers should not view it as a reduction in regulatory responsibilities. They will still have to comply with MHRA regulations, optimize EU-UK market access strategies, and enhance post-market surveillance and vigilance. This will ensure smooth and long-term access to the Great Britain market.
